Nuveen LLC Purchases New Shares in Cellebrite DI Ltd. $CLBT

Key Points

• Nuveen LLC has acquired a new stake in Cellebrite DI Ltd., purchasing 773,613 shares valued at approximately $15.03 million, which represents about 0.32% of the company.
• Wall Street analysts maintain an average rating of "Buy" for Cellebrite DI, with target prices ranging between $18.00 and $25.00, suggesting anticipated growth in the company's stock value.
• Cellebrite DI reported $0.12 earnings per share for the last quarter, exceeding estimates, with revenues up 18.4% year-over-year, indicative of solid financial performance.

Nuveen LLC bought a new stake in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 773,613 shares of the company's stock, valued at approximately $15,031,000. Nuveen LLC owned about 0.32% of Cellebrite DI at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in CLBT. Invesco Ltd. boosted its position in shares of Cellebrite DI by 122.1% in the first quarter. Invesco Ltd. now owns 3,296,079 shares of the company's stock worth $64,043,000 after purchasing an additional 1,811,757 shares during the period. Handelsbanken Fonder AB boosted its position in shares of Cellebrite DI by 749.9% in the first quarter. Handelsbanken Fonder AB now owns 1,518,700 shares of the company's stock worth $29,508,000 after purchasing an additional 1,340,000 shares during the period. Bank of New York Mellon Corp bought a new position in shares of Cellebrite DI in the first quarter worth approximately $22,428,000. AQR Capital Management LLC bought a new position in shares of Cellebrite DI in the fourth quarter worth approximately $16,205,000. Finally, Driehaus Capital Management LLC bought a new position in shares of Cellebrite DI in the fourth quarter worth approximately $11,959,000. 45.88% of the stock is owned by hedge funds and other institutional investors.

Cellebrite DI Stock Down 0.2%

Cellebrite DI stock traded down $0.03 during mid-day trading on Tuesday, reaching $15.80. 1,408,205 shares of the company's stock traded hands, compared to its average volume of 2,315,374. The company has a market cap of $3.78 billion, a price-to-earnings ratio of -20.79, a PEG ratio of 3.14 and a beta of 1.27. The stock has a 50 day moving average of $14.94 and a two-hundred day moving average of $17.34. Cellebrite DI Ltd. has a 12-month low of $13.10 and a 12-month high of $26.30.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last announced its earnings results on Thursday, August 14th. The company reported $0.12 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.01. Cellebrite DI had a negative net margin of 34.56% and a positive return on equity of 23.92%. The business had revenue of $113.28 million for the quarter, compared to the consensus estimate of $112.33 million. During the same quarter in the prior year, the firm posted $0.10 earnings per share. The business's revenue for the quarter was up 18.4% on a year-over-year basis. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, sell-side analysts forecast that Cellebrite DI Ltd. will post 0.3 earnings per share for the current year.

Wall Street Analysts Forecast Growth

CLBT has been the subject of a number of recent analyst reports. Wall Street Zen upgraded shares of Cellebrite DI from a "hold" rating to a "buy" rating in a research report on Saturday, August 16th. Needham & Company LLC dropped their price target on shares of Cellebrite DI from $24.00 to $18.00 and set a "buy" rating for the company in a research report on Thursday, August 14th. Lake Street Capital dropped their target price on shares of Cellebrite DI from $24.00 to $22.00 and set a "buy" rating for the company in a research report on Friday, August 15th. Finally, JPMorgan Chase & Co. dropped their target price on shares of Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating for the company in a research report on Monday, May 12th. Five investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $22.40.

Cellebrite DI Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.